Study Trial registration number Country Blind Sample size (female/male) Intervention Origin Dosage Route of medication Relevant outcomes Mean age (years) Follow-up Trial group Control group Trial group Control group Trial group Control group Kuah et al. [24 ] ACTRN12615000439549 Australia Double-blind 16 (5/11) 4 (3/1) MSC+placebo Placebo (cell culture media and cryopreservative) Human adipose tissue a: Intra-articular injection WOMAC, VAS, adverse events Low: 12 months Wang et al. [25 ] — China Not known 18 (8/10) 18 (7/11) MSC+sodium hyaluronate Sodium hyaluronate Human umbilical cord Intra-articular injection WOMAC 45-63 42-69 6 months Gupta et al. [26 ] NCT01453738 India Double-blind 20 (15/5) 10 (10/0) MSC+placebo Placebo (Plasmalyte A) Human bone marrow a: Intra-articular injection VAS, adverse events a: 12 months Yang et al. [27 ] — China Not known 28 (22/6) 16 (11/5) MSC+sodium hyaluronate Sodium hyaluronate Human umbilical cord a: Intra-articular injection VAS, adverse events a: 12 months Vega et al. [28 ] NCT01586312 Spain Blind for participants 15 (9/6) 15 (10/5) MSC+sodium hyaluronate Sodium hyaluronate Human bone marrow Intra-articular injection VAS, Lequesne, adverse events 12 months Hernigou et al. [29 ] — France Not known 30 (18/12) 30 (18/12) MSC+total knee arthroplasty Total knee arthroplasty Human bone marrow Intra-articular injection Adverse events, other clinical indicators 18-41 8-16 years Hou et al. [30 ] — China Not known 92 (52/40) 88 (50/38) MSC+sodium hyaluronate Sodium hyaluronate Human bone marrow Not known Intra-articular injection WOMAC 6 months Lamo-Espinosa et al. [31 , 32 ] NCT02123368 Spain Not known 20 (8/12) 10 (3/7) MSC+sodium hyaluronate Sodium hyaluronate Human bone marrow a: Intra-articular injection WOMAC, VAS, adverse events a: 65.9 (59.5, 70.6); b:57.8 (55.0, 60.8) 60.3 (55.1, 61.1) 4 years Lu et al. [33 ] — China Not known 40 (26/14) 40 (27/13) MSC+sodium hyaluronate Sodium hyaluronate Human bone marrow Not known Intra-articular injection WOMAC, adverse events 12 months Gan et al. [34 ] — China Not known 6 (5/1) 6 (4/2) MSC+sodium hyaluronate Sodium hyaluronate Human umbilical cord Not known Intra-articular injection WOMAC, Lequesne 12 months Vangsness et al. [35 ] NCT00225095 The US Double-blind 36 (not kwon) 19 (not kwon) MSC+sodium hyaluronate Sodium hyaluronate Human bone marrow a: Intra-articular injection VAS, adverse events — — 2 years Tan et al. [34 ] — China Not known 36 (26/10) 36 (27/9) MSC+arthroscopy cleanup Arthroscopy cleanup Human bone marrow Intra-articular injection Lequesne 12 months Wong et al. [36 ] — The US Not known 28 (13/15) 28 (14/14) MSC+sodium hyaluronate Sodium hyaluronate Human bone marrow Intra-articular injection Other clinical indicators 36-54 24-54 2 years Xu et al. [37 ] — China Not known 20 (not kwon) 20 (not kwon) MSC+arthroscopic surgery+sodium hyaluronate Arthroscopic surgery+sodium hyaluronate Human bone marrow Not known Intra-articular injection WOMAC 44-74 3 years Matas et al. [38 ] NCT02580695 Chile Double-blind 18 (11/7) 8 (5/3) MSC+sodium hyaluronate Sodium hyaluronate Human umbilical cord a: Intra-articular injection WOMAC, VAS, adverse events a: 54.8±4.5 12 months Ha et al. [39 ] — China Not known 89 (60/29) 86 (63/23) a: MSC+platelet-rich plasma v.s. platelet-rich plasma; b: MSC v.s. sodium hyaluronate+triamcinolone acetonide Human umbilical cord Intra-articular injection VAS, adverse events a: 12 months Lu et al. [40 ] NCT02162693 China Double-blind 26 (23/3) 26 (23/3) MSC+sodium hyaluronate Sodium hyaluronate Human adipose tissue Intra-articular injection WOMAC, VAS, adverse events 12 months Zhang et al. [41 ] NCT03955497 China Not known 14 (9/5) 14 (8/6) MSC+high tibial osteotomy High tibial osteotomy Human adipose tissue Not known Intra-articular injection WOMAC, VAS 12 months Liang et al. [42 ] — China Not known 26 (not known) MSC Placebo Human bone marrow Intra-articular injection WOMAC, adverse events 40-65 4 weeks Zhou [43 ] — China Not known 54 (not known) 54 (not known) MSC+sodium hyaluronate Conventional therapy Not known Not known Intra-articular injection WOMAC, VAS 3 months Freitag et al. [44 ] ACTRN12614000814673 Australia Not known 20 (9/11) 10 (5/5) MSC Conventional therapy Human adipose tissue a: Intra-articular injection WOMAC, adverse events a: 6 months Lee et al. [45 ] — South Korea Double-blind 12 (9/3) 12 (9/3) MSC Normal saline Human adipose tissue Intra-articular injection WOMAC, VAS, adverse events 6 months Garza et al. [46 ] NCT02726945 The US Double-blind 26 (11/15) 13 (7/6) MSC Placebo Human stromal vascular fraction a: Intra-articular injection WOMAC, adverse events a: 12 months Lamo-Espinosa et al. [47 ] NCT02365142 Spain Not known 24 (7/17) 26 (10/16) MSC+platelet-rich plasma Platelet-rich plasma Human bone marrow Intra-articular injection WOMAC, VAS, adverse events 40-62 33-70 12 months Bastos et al. [48 ] — Multi-center Double-blind 30 (15/15) 17 (8/9) a: MSC+platelet rich plasma; b: MSC Corticosteroid Human bone marrow Not known Intra-articular injection Other clinical indicators a: 12 months Hong et al. [49 ] ChiCTR1800015125 China Double-blind, but does not describe the implementation MSC in left: 8 (7/1); MSC in right 8 (6/2) MSC+sodium hyaluronate Sodium hyaluronate Human adipose tissue Not known Intra-articular injection WOMAC, VAS, adverse events MSC in left: 12 months Khalifeh Soltani et al. [50 ] IRCT2015101823298N Iran Double-blind 10 (not known) 10 (not known) MSC Normal saline Human placenta Intra-articular injection VAS, adverse events 35-75 24 weeks Zhang et al. [51 ] — China Blind for outcome assessment 72 (56/16) 36 (8/28) MSC+sodium hyaluronate or MSC only Sodium hyaluronate Human adipose tissue Not known Intra-articular injection WOMAC, VAS a: 3 years
